Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +2.39%63 3-1 Month Momentum % is -33.24% as of Jul. 17, 2026. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued). Among 1,022 Drug Manufacturers companies, Zoetis ranks worse than 93.15% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-17), Zoetis's 3-1 Month Momentum % is -33.24%.
The industry rank for Zoetis's 3-1 Month Momentum % or its related term are showing as below:
XSWX:ZTS's 3-1 Month Momentum % is ranked worse than 93.15% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -9.1
vs XSWX:ZTS: -33.24
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Zoetis 3-1 Month Momentum % Related Terms
XSWX:ZTS vs UTHR, VTRS, NBIX: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Zoetis's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (XSWX:ZTS) has a 3-1 Month Momentum % of -33.24% as of Jul. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zoetis and its competitors. According to the industry distribution chart, Zoetis ranks #952 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 93.2%.
Is Zoetis' 3-1 Month Momentum % too high?
Zoetis' current 3-1 Month Momentum % is -33.24%. Based on the distribution chart, Zoetis ranks #952 out of 1022 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' 3-1 Month Momentum % compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #952 out of 1022 companies for 3-1 Month Momentum %. This places Zoetis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zoetis and its competitors. Zoetis's current 3-1 Month Momentum % is -33.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current 3-1 Month Momentum % is -33.24%. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current 3-1 Month Momentum % is -33.24% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
3-1 Month Momentum %: -33.24%
GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score
Get the complete analysis for XSWX:ZTS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
